Letrozole Zydus

Letrozole, the active ingredient in Letrozole Zydus, is an aromatase inhibitor presented as an oral tablet for oral use. It is used to treat estrogen receptor‑positive breast cancer in postmenopausal women. GNH USA supplies Letrozole Zydus as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres worldwide.

Letrozole is an aromatase inhibitor indicated for hormone‑driven breast cancer conditions. - Estrogen receptor‑positive breast cancer (postmenopausal): Reduces tumour growth and recurrence risk. - Advanced or metastatic breast cancer (postmenopausal): Delays disease progression. - Adjuvant therapy after surgery (postmenopausal): Improves disease‑free survival.

Adverse reactions may occur with Letrozole therapy.

Common Side Effects: - Hot flashes: Sudden feeling of warmth, often with sweating. - Arthralgia: Joint pain or stiffness. - Fatigue: Persistent tiredness not relieved by rest. - Nausea: Mild to moderate upset stomach. - Headache: Pressure or throbbing pain in the head.

Serious or Rare Side Effects: - Severe liver injury: Jaundice, dark urine, elevated enzymes. - Bone fracture: Increased risk of osteoporosis‑related breaks. - Deep vein thrombosis or pulmonary embolism: Swelling, pain, or shortness of breath. - Anaphylaxis: Rapid onset of rash, swelling, and breathing difficulty. - QT interval prolongation: Potential cardiac arrhythmia.

Patients should be monitored for safety concerns before and during treatment. - Bone health monitoring: Assess bone mineral density periodically. - Liver function tests: Check hepatic enzymes at baseline and during therapy. - Cardiovascular assessment: Evaluate risk factors for thrombosis. - Pregnancy avoidance: Contraindicated in pregnancy; ensure effective contraception. - Elderly caution: Adjust monitoring for older patients with comorbidities. - Store at below 25°C: Keep in the original packaging, protect from moisture and direct sunlight.

Letrozole may interact with other medicines, altering efficacy or safety.

Major Interactions (Avoid): - Combined estrogen therapy: Negates aromatase inhibition. - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): Reduce plasma levels of letrozole. - Antifungal azoles (e.g., ketoconazole): May increase letrozole exposure.

Moderate Interactions (Monitor Closely): - CYP2C19 inhibitors (e.g., fluoxetine): Slightly raise letrozole concentrations. - Warfarin: May enhance anticoagulant effect; monitor INR. - Statins (e.g., simvastatin): Potential for increased muscle toxicity. - Glucocorticoids: May affect hormone balance; observe clinical response.